Moderna's Stock Soars on Cancer Vaccine Data, But Wall Street Remains Cautiously Optimistic
Despite a stellar year-to-date performance fueled by promising clinical trial results, analyst sentiment on Moderna remains tempered, with a consensus 'Hold' rating highlighting the challenges beyond its COVID-19 windfall.